Cellectis (CLLS) Return on Capital Employed (2015 - 2026)
Cellectis' (CLLS) quarterly Return on Capital Employed came in at 25.55% in Q1 2026, down 54.0% year-on-year from 55.55% in Q1 2025, and down 45.33% quarter-over-quarter from 17.58% in Q4 2025.
Cellectis (CLLS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Cellectis' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 25.55% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 54.0% year-over-year to 25.55% in Q1 2026; TTM through Mar 2026 was 25.55%, a 54.0% decrease from a year earlier, with the FY2025 full-year figure at 28.58%, up 234.0% from the prior year.
- Return on Capital Employed fell to 25.55% in Q1 2026 per CLLS's latest filing, from 17.58% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.21% in Q3 2025 and bottomed at 83.28% in Q4 2023.
- The 5-year median for Return on Capital Employed is 39.95% (2024), against an average of 37.18%.
- Across the five-year window, Return on Capital Employed plunged 4299 bps in 2023 and jumped 5662 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 40.29% in 2022, then tumbled by 107 bps to 83.28% in 2023, then soared by 68 bps to 26.65% in 2024, then surged by 34 bps to 17.58% in 2025, then slumped by 45 bps to 25.55% in 2026.
- Per Business Quant, the three latest CLLS Return on Capital Employed figures stand at 25.55% (Q1 2026), 17.58% (Q4 2025), and 13.21% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -25.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.55% |
| Dec 31, 2025 | -17.58% |
| Sep 30, 2025 | -13.21% |
| Jun 30, 2025 | -23.60% |
| Mar 31, 2025 | -25.01% |
| Dec 31, 2024 | -26.65% |
| Sep 30, 2024 | -33.26% |
| Jun 30, 2024 | -39.95% |
| Mar 31, 2024 | -50.97% |
| Dec 31, 2023 | -83.28% |
| Sep 30, 2023 | -42.00% |
| Jun 30, 2023 | -40.54% |
| Mar 31, 2023 | -39.29% |
| Dec 31, 2022 | -40.29% |
| Sep 30, 2022 | -43.87% |
| Jun 30, 2022 | -44.29% |
| Mar 31, 2022 | -42.79% |
| Dec 31, 2021 | -35.71% |
| Sep 30, 2021 | -36.02% |
| Jun 30, 2021 | -31.58% |